Harmony Biosciences(HRMY)
Focus: Harmony Biosciences is a publicly traded specialty biotech focused on sleep and CNS disorders, generating $582M in revenue (FY2025) entirely from its lead product WAKIX (pitolisant).
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
12+2 this month
Stable — net +2 jobs in 30d
10 added, 8 removed. Backfill posture.
Should You Work at Harmony Biosciences?
AI assessmentHarmony offers near-term financial stability and CNS expertise but carries substantial long-term career risk due to single-product dependency and patent cliff in 5 years.
Why Work Here
- Profitable, cash-generative company with $453M cash position and 22% YoY revenue growth, providing stability and investment capacity.
- Focused portfolio in high-unmet-need CNS space with 6 Phase 3 programs (pitolisant expansion into idiopathic hypersomnia, Prader-Willi syndrome; clemizole in Dravet and Lennox-Gastaut syndromes) offering clear clinical advancement opportunities.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
8 Phase 3+
LOE Risk
1 in 5yr
WAKIX
Hiring
Stable
Revenue
$582M
Key Products
$101M Part DStable
Peak3.6yr
Sole revenue driver (100% of sales) — any market erosion directly impacts company viability; expiration triggers existential business transition.
Help build intelligence for Harmony Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.